The enzyme 11␤-hydroxysteroid dehydrogenase type 2 (11BHSD2) converts cortisol to cortisone in the kidney, thereby protecting the mineralocorticoid receptor from the mineralocorticoid actions of cortisol. The syndrome of Apparent Mineralocorticoid Excess (AME), a rare monogenic form of early onset hypertension with autosomal recessive inheritance, is caused by homozygous or compound heterozygous loss of function mutations in the 11BHSD2 gene. Association has been reported between a microsatellite marker flanking the 11BHSD2 gene (D16S496) and primary hypertension. The aim of this study was to identify variants in the 11BHSD2 gene and to test if such variants or the D16S496 are associated with primary hypertension, in Swedes. To address this, the coding sequences of the 11BHSD2 gene was screened for mutations in 20 patients with primary hypertension with single strand conformation polymorphism and direct DNA sequencing techniques. A poly-
Introduction
Cortisol circulates in the bloodstream in much higher concentrations than aldosterone does and the two hormones bind with the same affinity to the mineralocorticoid receptor in vitro. 1 However, the enzyme 11␤-hydroxysteroid dehydrogenase type 2 (11BHSD2) protects the mineralocorticoid receptor from the mineralocorticoid actions of cortisol by converting cortisol to cortisone. [2] [3] [4] Cortisone has a low affinity for the mineralocorticoid receptor 5, 6 and aldosterone is therefore the major mineralocorticoid in vivo. The 11BHSD2 gene is located on chromosome 16q22 7 and is expressed at high levels in the kidney, colon and placenta. 4, 8, 9 The syndrome of Apparent Mineralocorticoid Excess (AME) is a rare monogenic form of hypertension with autosomal recessive inheritance and is caused by homozygous or compound heterozygous Correspondence: Olle Melander, Department of Endocrinology, Malmö University Hospital MAS, S-205 02 Malmo, Sweden. Fax: 00 46 40 337042, E-mail: Olle.MelanderȰendo.mas.lu.se morphism was identified in exon 3; G534A (Glu178Glu). This polymorphism and the D16S496 microsatellite were tested for association with primary hypertension in a population consisting of 292 patients with primary hypertension and 263 normotensive control subjects. The frequency of G534G homozygotes was higher in patients with primary hypertension than in normotensive control subjects (92.8% vs 87.8%; P Ͻ 0.05). The allele frequencies of the D16S496 microsatellite did not differ between the two groups ( 2 ‫؍‬ 11.0, df ‫؍‬ 10; P ‫؍‬ 0.36). In conclusion, over-representation of individuals homozygous for the G534 allele in hypertensive patients compared with control subjects suggests that a mutation in linkage disequilibrium with the G534A polymorphism could increase susceptibility to primary hypertension. Journal of Human Hypertension (2000) 14, 819-823 loss of function mutations in the 11BHSD2 gene. [10] [11] [12] [13] [14] The reduced activity of the mutated 11BHSD2 enzyme allows unconverted cortisol to stimulate the mineralocorticoid receptor in the kidney, resulting in early onset of hypertension due to renal sodium retention, hypokalaemic alkalosis, suppression of the renin-angiotensin-aldosterone system and an elevated ratio of cortisol to cortisone metabolites in urine. [10] [11] [12] [13] [14] Treatment with aldosterone receptor antagonists, like spironolactone, reverses the condition. 10 Although the clinical picture seem to be typical in the majority of AME patients, a milder form of AME with low-renin hypertension and hypoaldosteronism but normal potassium values and no alkalosis has also been described. 15 This suggests that mutations in the 11BHSD2 gene may be a more common cause of low-renin hypertension, which is a frequent feature in patients with primary hypertension. 16 Furthermore, a subset of patients with primary hypertension are characterised by prolonged half-life of cortisol and increased excretion of urinary cortisol metabolites. 17, 18 A polymorphic microsatellite marker flanking the 11BHSD2 gene (D16S496) has been reported to be associated with primary hypertension. 19 We therefore hypothesised that the 11BHSD2 gene could contain variants which decrease the activity of the enzyme and thereby contribute to the pathogenesis of primary hypertension. The aim of this study was to identify variants in the 11BHSD2 gene and to test if such variants or the D16S496 are associated with primary hypertension, in Swedes.
Methods

Subjects
All study subjects were recruited from health care centres in the Scania and Skaraborg regions in southern Sweden. The diagnosis of primary hypertension was based on at least three blood pressure recordings above 160/90 mm Hg at different occasions, in the absence of any clinical signs of secondary hypertension.
Mutation screening of the 11BHSD2 gene was performed in 20 unrelated patients (10 men and 10 women) with early onset of primary hypertension ). All patients were on chronic pharmacological antihypertensive treatment and had at least one first-degree relative with primary hypertension. None of them had diabetes mellitus or kidney disease.
A total of 292 unrelated patients with primary hypertension and 263 unrelated normotensive control subjects were genotyped for the G534A polymorphism and for the D16S496 microsatellite marker. The diagnosis of primary hypertension was established before the age of 60 years and all of the patients were on chronic pharmacological antihypertensive treatment. Subjects with diabetes mellitus or kidney disease were excluded. The normotensive control subjects were selected as follows: (1) age at the time of the study у40 years; (2) systolic-and diastolic blood pressure of р150 mm Hg and р80 mm Hg, respectively; (3) no personal history of elevated blood pressure, diabetes mellitus or any other chronic disease; (4) absence of medication; and (5) no family history of hypertension in first-degree relatives (Table 1) . ) 86.0 ± 9.9 71.5 ± 7.1 Ͻ0.0001 Age at onset of hypertension (years) 46.4 ± 9.5 --Blood pressure was measured in the supine position after 5-min rest with a sphygmomanometer by specially trained nurses. Height was measured to the nearest centimetre and weight to the nearest 0.1 kg. BMI was calculated as the ratio of the weight in kg to the square of the height in metres (kg/m 2 ). Serum potassium concentrations were measured by standard biochemical methods.
All study participants had given a written informed consent and the study was approved by the ethics committee of the Medical Faculty of Lund University.
Mutation screening of the 11BHSD2 gene
Total genomic DNA was extracted from venous blood by standard methods. 20 The coding sequences of the five exons of the 11BHSD2 gene, the 5Ј-untranslated region, 40-84 base pairs up-and downstream of exons 1-4, 45 base pairs upstream of exon 5 and 45 base pairs downstream of the stop codon in exon 5 were amplified with polymerase chain reaction (PCR) and analysed by the single strand conformation polymorphism technique. 21 Eight sets of primers were designed according to the published genomic sequence of the 11BHSD2 gene 7 resulting in PCR fragments sizes of 223-303 base pairs ( Table  2) . Exons 1, 2 and 5 were amplified in two fragments (fragments 1A-B, 2A-B and 5A-B) and exons 3 and 4 in one fragment (fragment 3-4) ( Table 2 ). PCR:s were performed with 50 ng genomic DNA in a total volume of 20 l containing 10 pmol of each primer, 2 nmol dNTPs, 2% formamide, 0.05 l [␣- 32 ]dCTP (3.000 Ci/mmol), (Amersham, Sweden AB, Solna, Sweden) and 1 U Taq polymerase (Perkin Elmer, Foster City, CA, USA) in either 1 × PCR buffer as recommended by the manufacturer (Perkin Elmer) (fragments 2A, 3, and 5B) or in 1 × (NH 4 ) 2 SO 4 -buffer (16 mmol/l (NH 4 ) 2 SO 4 ; 67 mmol/l Tris pH 8.8; 0.01% Tween) (fragments 1A-B, 2B, 4 and 5A). Reactions were performed in either 1.5 mmol/l MgCl 2 (fragments 1A-B, 2B, 3-4 and 5B) or 3.0 mmol/l MgCl 2 (fragments 2A and 5A). PCR conditions were as follows: initial denaturation at 94°C for 5 min, followed by 30 cycles (except for fragments 5A and 5B which had 35 and 28 cycles, respectively) of denaturation (94°C for 30 sec), annealing (61°C for fragment 1B; 62°C for fragments 2B, 4 and 5A; 63°C for fragment 1A, 64°C for fragment 3, 65°C for fragment 2A and 66°C for fragment 5B; for 30 sec) and extension (72°C for 30 sec), with the final extension at 72°C for 10 min. Reactions were diluted 1:1 with 95% formamide buffer, denatured for 5 min at 90°C, cooled, and electrophoresed on glycerol free (35 W for 4 h at 4°C) and 5% glycerol (8 W for 13 h at room temperature), non-denaturating 5% polyacrylamide gels (acrylamide/bisacrylamide 49:1). When differences in band pattern were observed, the PCR products were sequenced bidirectionally using the ABI PRISM Dye Terminator Cycle Sequencing Ready Reaction Kit (Perkin Elmer) in an ABI PRISM 373 automated DNA Sequencer (Perkin Elmer). CCAGCGCCGCCAGCAGCGG  272  1B  TGCCCGCGCGCTGCTGCAG  AGTCCCGCCCTCGAGCCTGG  269  2A  GGCTAGGCTGGGCCACAGC  GGTGAACTCTAGCACGCGGC  241  2B  GGTGCTGGCCACCGTATTGG  AACTTCCAGTCCCCGTGTCC  223  3  CTGCTGGGCTGACCTAAGGC  GGCAAGGGGCTCCCTAAGCC  303  4  GGCTTAGGGAGCCCCTTGCC  CATTCATCAAACCTGACCTGCC  278  5A  GCTCCCCTAGCTGATCCCAG  GTAGTGGATGAAGTACATGAGCC  299  5B  GCGCTGCTGGCAGCTCGGC  CGGAGCCTCCTGTGCTGCAG  282 bp, base pairs.
Genotyping
To confirm and to simplify the detection of the G534A polymorphism in exon 3, restriction fragment length polymorphism methods were developed. The same forward primer as in the mutation screening of exon 3 ( Table 2 ) was used together with a new reverse primer (5Ј-CCTTGAGCTGCGCAGCAGG), designed according to the published genomic sequence of the 11BHSD2 gene, 7 to perform a non-radioactive PCR with 50 ng genomic DNA in a total volume of 20 l containing 10 pmol of each primer, 2 nmol dNTPs, 2% formamide and 1 U Taq polymerase (Perkin Elmer) in 1 × PCR buffer as recommended by the manufacturer (Perkin Elmer). Reactions were performed in 3.0 mmol/l MgCl 2 . PCR conditions were as follows: initial denaturation at 94°C for 5 min, followed by 32 cycles of denaturation (94°C for 30 sec), annealing (62°C for 30 sec) and extension (72°for 30 sec), with the final extension at 72°for 10 min. The PCR product was digested with the restriction enzyme Alul (New England Biolabs, Beverly, MA, USA) which cleaves the G534 variant, using the buffer and digestion condition recommended by the manufacturer. The fragments were separated on agarose gels after staining with ethidium bromide and visualised under ultraviolet light.
A gene segment surrounding the D16S496 microsatellite marker 19, 22 was amplified with PCR using a 5Ј-end ␥-32 P-ATP labelled (Amersham, Sweden AB, Solna, Sweden) forward primer (5Ј-TAGTAATAGGATCATACTACTTG) and a reverse primer (5Ј-ATAAGCCACTGCGCCCATC). The primers were designed according to the published genomic sequence surrounding D16S496. 22 PCR was performed with 37.5 ng of genomic DNA in a total volume of 15 l containing 3 pmol of each primer, 2 nmol dNTPs, 1 U Taq polymerase (Perkin Elmer) in 1 × PCR-buffer (Perkin Elmer), 3% formamide and 1.5 mmol/l MgCl 2 . PCR conditions were as follows: initial denaturation at 94°C for 5 min, followed by 30 cycles of denaturation (94°C for 30 sec), annealing (58°C for 30 sec) and extension (72°C for 30 sec), with the final extension at 72°C for 10 min. Genotypes were analysed through electrophoresis on a 5% urea denaturating polyacrylamide gel followed by autoradiography. In four subjects, genotyping of the D16S496 microsatellite failed. 
Journal of Human Hypertension
Results
In the mutation screening of the 11BHSD2 gene in 20 patients with early onset of primary hypertension one polymorphism was identified, substituting a G to an A at nucleotide position 534 at codon 178 [G534A (Glu178Glu)]. The genotype frequency distributions observed for the G534A polymorphism in the population association study (Table 3) were Table 3 Genotype frequency distribution of the G534A variant and blood pressure-and serum potassium values according to different genotypes. Data are means ± s.d.
G534G
G534A A534A
Hypertensive patients (n = 292) Genotypes, n (%) 271 (92. similar to those expected from the allele frequencies according to the Hardy-Weinberg equilibrium. Only one individual had the A534A genotype (Table 3) and the G534A and A534A genotypes were therefore pooled. The frequency of G534G homozygotes was significantly higher among patients with primary hypertension (G534G, 92.8%, n = 271 and G534A/A534A, 7.2%, n = 21) compared to normotensive control subjects (G534G, 87.8%, n = 231 and G534A/A534A, 12.2%, n = 32) (P Ͻ 0.05). After adjustment for age, sex and BMI the OR for hypertension in G534G homozygotes was 1.8 (95% CI = 1.0-3.3) . The allele frequency distribution did not differ significantly between the patients with hypertension (G534 96.2% and A534 3.8%) and the control subjects (G534 93.9% and A534 6.1%) (P = 0.07). There was no significant difference in blood pressure or serum potassium values between carriers of the different G534A genotypes either among the patients with primary hypertension (who were all on antihypertensive treatment) or among the normotensive control subjects ( Table 3) .
Genotyping of the D16S496 microsatellite revealed 11 different alleles. There was no significant difference in the allele frequency of the D16S496 between the patients with primary hypertension and the normotensive control subjects ( 2 = 11.0, df = 10; P = 0.36). We also studied genotype combinations of markers G534A and D16S496 to explore if there was allelic association between the G534 allele and any of the D16S496 alleles and if the frequency distribution of the genotype combinations differed between patients with primary hypertension and normotensive controls. The G534 allele was found in combination with all the different alleles of the D16S496 microsatellite and totally 48 different genotype combinations were found, indicating no allelic association between the two markers in the population. Nor did the frequency distribution of genotype combinations differ significantly between the two groups (data not shown).
Discussion
This study was designed to evaluate the role of the 11BHSD2 gene in primary hypertension. Mutation screening of the coding parts of the gene revealed a silent polymorphism (G534A). Homozygous carriers of the G534 allele had an age, sex and BMI adjusted OR for hypertension of 1.8 (95%CI = 1.0-3.3) compared with carriers of the other genotypes. The microsatellite marker D16S496 flanking the 11BHSD2 gene, which has earlier been reported to be associated with primary hypertension in blacks, 19 was not associated with hypertension in our study population. There was no linkage disequilibrium between the G534A-and D16S496 markers.
The G534A polymorphism does not change the predicted amino acid sequence of the 11BHSD2 enzyme and is therefore unlikely to be of any functional significance. However, the observed association between the G534G genotype and primary hypertension could be caused by a mutation which affects 11BHSD2 expression or activity and is in linkage disequlibrium with the G534A polymorphism. The lack of association between the G534G genotype and higher blood pressure levels within the group of patients with hypertension (Table 3) is not surprising as they were all on antihypertensive medication. It was more surprising that we did not see such an association among the normotensive control subjects (Table 3) . One possible explanation for this is that other blood pressure regulatory mechanisms are able to compensate for the blood pressure elevating effect associated with the presence of the G534G genotype as long as you are in the normotensive blood pressure range, whereas at higher levels of blood pressure (due to other genes and environmental factors) the blood pressure elevating effect of the G534G genotype may not be compensated for as effectively.
The G534A polymorphism has been described earlier, 23, 24 but was not associated with primary hypertension in Swiss 23 or French 24 populations. The former study 23 only investigated 41 patients with primary hypertension and could therefore be underpowered, however, the latter study included over 1000 patients with primary hypertension and over 300 normotensive controls but still found no significant association to hypertension. 24 This discrepancy could be due to the G534A polymorphism being in linkage disequilibrium with a functional mutation affecting blood pressure in our Swedish population but not in the French and Swiss populations 23, 24 or due to differences in genetic and environmental background factors between the populations. The hypothesis that the 11BHSD2 gene may be of importance for blood pressure regulation was recently supported by a study reporting a significantly higher ratio of cortisol to cortisone metabolites in urine in salt sensitive as compared to salt resistant subjects indicating that salt sensitive subjects, like the patients with AME, have a reduced activity of the 11BHSD2 enzyme. In addition, a microsatellite marker flanking the 11BHSD2 gene was associated with both salt sensitivity and the cortisol to cortisone metabolite ratio in urine. 25 Interestingly, in the same study it was shown that subjects carrying the G534G genotype had a significantly higher cortisol to cortisone metabolite ratio in urine compared to carriers of the G534A and A534A genotypes. 25 This finding suggests that the pathophysiological mechanism underlying the association between the G534G genotype and hypertension in our population, is indeed a reduced capacity of the 11BHSD2 enzyme to protect the mineralocorticoid receptor from being stimulated by cortisol. In conclusion, the overrepresentation of individuals homozygous for the G534 allele in hypertensive patients compared with control subjects suggests that a mutation in linkage disequilibrium with the G534A polymorphism could increase susceptibility to primary hypertension.
